Medical experts illustrate the nature of hemolysis in PNH and characteristics unique to the disease state. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the ...

AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...

The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...

ASH 2025 highlighted many investigational agents for paroxysmal nocturnal hemoglobinuria (PNH) that may not reach clinical practice soon, notes Dr Jamile M. Shammo, though bispecific antibodies show ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...